Nanotechnology-Based Pharmacological Treatment for Brain Tumors
DOI:
https://doi.org/10.54097/7278ey80Keywords:
Brain Tumors; Nanotechnology-Based; Treatment.Abstract
One of the most aggressive forms of cancer, brain tumors, especially glioblastoma multiforme (GBM), have a short survival period and a high death rate. It is estimated that 94,390 new cases of primary brain and other central nervous system (CNS) tumors would occur in the United States alone in 2023. The blood-brain barrier's (BBB) protective role and the aggressive nature of GBM provide significant therapeutic challenges. The inability to accurately target tumor cells without harming nearby healthy tissue, poor drug penetration through the blood-brain barrier, and resistance to conventional therapies are some of the drawbacks of current treatments like radiation, chemotherapy, and surgery. A potential solution to these issues is drug delivery systems based on nanotechnology. Nanoparticles, such as carbon-based nanomaterials, liposomes, and polymeric nanoparticles, enhance drug solubility, target certain cells, and enable controlled release. Because of this, therapeutic medications can more easily cross the blood-brain barrier and build up at the tumor site, reducing systemic toxicity. With an emphasis on the advantages of various nanoparticle systems, such as liposomes, polymeric nanoparticles, stimulus-responsive nanoparticles, and carbon nanotubes, this study explores the application of nanotechnology in the treatment of brain tumors. The study examines the shortcomings of existing treatments for brain cancer and how nanodelivery systems can address these issues, ultimately providing a response to the following research question: How can drug delivery systems based on nanotechnology enhance the effectiveness of treatments for brain tumors?.
Downloads
References
[1] Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro-oncology, 2023, 25(12 Suppl 2), iv1-iv99.
[2] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2024, 74(3), 229-263.
[3] Thierheimer, M., Cioffi, G., Waite, K. A., Kruchko, C., Ostrom, Q. T., & Barnholtz-Sloan, J. S. Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex. Journal of neurooncology, 2023, 162(1), 167-177.
[4] Comba, A., Li, X., & Breznik, B. . Editorial: Brain cancer pathogenesis and data integration. Frontiers in genetics, 2023, 14, 1298285.
[5] Qiu, Z., Yu, Z., Xu, T., Wang, L., Meng, N., Jin, H., & Xu, B. Novel Nano-Drug Delivery System for Brain Tumor Treatment. Cells, 2022, 11(23), 3761.
[6] Miao, Y. B., Zhao, W., Renchi, G., Gong, Y., & Shi, Y. Customizing delivery nano-vehicles for precise brain tumor therapy. Journal of nanobiotechnology, 2023, 21(1), 32.
[7] Ali, M. R. K. , Wu, Y. , & El-Sayed, M. A. Gold-nanoparticle-assisted plasmonic photothermal therapy advances toward clinical application. The Journal of Physical Chemistry C, 2019, 123(25).
[8] Wang J, Xu H, Ge S, Xue C, Li H, Jing X, Liang K, Zhang X, Zhang C. EHMT2 (G9a) activation in mantle cell lymphoma and its associated DNA methylation and gene expression. Cancer Biol Med. 2021, 19(6):836–49.
[9] Lai, C. H., Wu, W. C., Tsai, M. C., & Chen, Y. J. Transferrin-conjugated liposomes as brain-targeted chemotherapy for glioblastoma treatment. Journal of Controlled Release, 2013, 172(2), 602–611.
[10] []Immordino, M. L., Dosio, F., & Cattel, L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine, 2006, 1(3), 297-315.
[11] Ko, Y. T., Bhattacharya, R., & Bickel, U. Liposomal drug delivery systems for enhanced delivery of drugs to the brain. Advanced Drug Delivery Reviews, 2020, 160, 38-54.
[12] Pradhan, P., Giri, J., Banerjee, R., Bellare, J. & Bahadur, D. Magnetic nanoparticles for hyperthermia-based therapy and controlled drug delivery applications. Advanced Drug Delivery Reviews, 2018, 39(3), 69-83.
[13] Wang, Y., Zhou, K., Huang, G., & Huo, X. Development of pH-sensitive nanoparticles for glioblastoma therapy. Materials Science & Engineering C, 2020, 114, 111052.
[14] Liu, Y., Zhang, L., Feng, J., Zhang, X., Wang, Y., & Yu, X. Temperature-sensitive liposomes for glioblastoma treatment by hyperthermia. Journal of Biomedical Nanotechnology, 2019, 15(4), 787-798.
[15] Zhu, L., Wang, Y., Zhao, Y., & Yang, L. Enzyme-responsive nanoparticles for targeted delivery to glioblastoma. Theranostics, 2021, 11(12), 5741–5754.
[16] Liu, X., Li, W., Yang, Y., & Xiong, R. Functionalized carbon nanotubes for drug delivery to gliomas. Carbon, 2020, 158, 105-114.
[17] Zhang, Y., Wu, J., Lv, H., Chen, H., & Liu, D. CNT-based biosensor for glioma diagnosis: Application of carbon nanotubes in tumor biomarker detection. Sensors and Actuators B: Chemical, 2019, 301, 127067.
[18] Singh, P., Kumar, V., & Goyal, R. N. CNT-based quantum dot biosensor for miRNA detection in brain tumor diagnosis. Biosensors and Bioelectronics, 2021, 183, 113207.
[19] Montemurro, N., Ricciardi, L., & Comito, M. Recurrence of glioblastoma after maximal resection: When and why does it happen? Frontiers in Oncology, 2020, 10, 1660.
[20] Kong, X., Chen, X., Liu, H., & Zhao, Y. Transferrin-conjugated PEGylated liposomes for enhanced targeting of glioblastoma multiforme. Journal of Controlled Release, 2021, 332, 1-12.
[21] Veronesi, M. C., Quarto, R., & Conti, B. PLGA nanoparticles loaded with temozolomide for enhanced brain tumor therapy. Molecular Pharmaceutics, 19(4), 2022, 1451-1460.
[22] Zhou, Z., Zhao, X., Wang, X., & Zhang, L. pH-sensitive nanoparticles for targeted therapy of glioblastoma: A preclinical study. Theranostics, 2022, 12(3), 725-738.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
